老年人疫苗研究最新进展
本文是《Age and Ageing》疫苗专辑的评论文章,聚焦老年人流感、新冠、呼吸道合胞病毒和肺炎球菌疫苗的接种率、效果及新兴研究优先方向。文章指出接种率国际差异大且受疫苗犹豫挑战,新冠疫苗对养老院居民防感染和死亡有显著保护但效果随时间下降,观察性数据显示部分疫苗可能与痴呆风险降低相关但因果关系未证实。
要点
- 推荐疫苗接种率国际差异大,受疫苗犹豫挑战,成功项目需结合医护人员教育、集中提醒和便捷服务。
- 养老院居民研究显示新冠疫苗对感染和死亡有显著保护,但效果随时间下降并受免疫衰老影响。
- 观察性数据显示部分疫苗可能与痴呆风险降低相关,尤其血管性痴呆,但因果关系未证实。
核心结论
- 疫苗接种是健康老龄化和老年医学的基石,其作用可能超越感染预防而影响更广泛健康结局。
研究设计与样本
- 本文为评论文章,纪念《Age and Ageing》疫苗专辑发布,重点回顾该期刊已发表的疫苗相关研究。
主要发现
- 推荐疫苗(流感、新冠、呼吸道合胞病毒、肺炎球菌)接种率国际差异大,受疫苗犹豫挑战。
- 养老院居民研究显示新冠疫苗对感染尤其死亡有显著保护,但效果随时间下降并受免疫衰老影响。
- 免疫学研究显示未感染过的老年人疫苗反应较弱,支持加强针和增强免疫策略的重要性。
- 新兴证据提示益生菌等干预可能改善疫苗免疫原性,但需进一步高质量试验。
- 观察性数据显示部分疫苗可能与痴呆风险降低相关,尤其血管性痴呆,但因果关系未证实。
关键数值与推荐
- 成功疫苗接种项目结合医护人员教育、集中提醒系统和便捷接种服务。
- 未来需更多纳入衰弱老年人和养老院居民进入疫苗试验以强化证据基础。
临床怎么用
- 老年医学科应重视推荐疫苗接种,结合医护人员教育、提醒系统和便捷服务提高接种率。
- 对养老院居民和衰弱老年人应关注新冠疫苗加强接种,因效果随时间下降。
- 可关注益生菌等改善疫苗免疫原性的新兴证据,但需等待高质量试验验证。
局限性
- 本文为评论文章,非系统综述或原始研究,未提供具体数值、样本量或效应量。
- 疫苗与痴呆风险降低的关联来自观察性数据,因果关系未证实。
- 益生菌改善疫苗免疫原性的证据尚需进一步高质量试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is increasingly recognised as a cornerstone of healthy ageing and geriatric care, extending beyond the prevention of infectious disease to potentially influence broader health outcomes. This Commentary article commemorates the launch of Age and Ageing's vaccines collection by highlighting key vaccine-related research published in the journal. It focuses on vaccine uptake, effectiveness and emerging research priorities for older adults. Uptake of recommended vaccines, including influenza, COVID-19, respiratory syncytial virus and pneumococcal vaccines, remains variable internationally and is challenged by vaccine hesitancy. Successful vaccination programmes combine healthcare professional education, centralised reminder systems and easy access to vaccination services. Studies involving care-home residents demonstrated that COVID-19 vaccines provided substantial protection against infection and, particularly, mortality, although effectiveness declines over time and is influenced by immunosenescence. Immunological studies reveal weaker vaccine responses among infection-naïve older adults, supporting the importance of booster programmes and strategies to enhance immunity. Emerging evidence also suggests that interventions such as probiotics may improve vaccine immunogenicity, although further high-quality trials are required. Beyond infection prevention, observational data indicate that several vaccines, may be associated with a reduced risk of dementia, particularly vascular dementia, though causal relationships remain unproven. Looking forward, greater inclusion of frail older adults and care home residents in vaccine trials is essential to strengthen the evidence base. Future research should support the development of novel vaccines, improve preparedness for future pandemics and optimise vaccination strategies to maximise healthy ageing and preserve function in later life.
引用
- Soiza RL, Veronese N. Recent research on vaccines for older adults. Age Ageing. 2026. PMID: 42933996. doi:10.1093/ageing/afag313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。